K2M Group Holdings Inc (NASDAQ:KTWO) – Equities researchers at William Blair reduced their FY2017 earnings per share (EPS) estimates for K2M Group in a note issued to investors on Monday. William Blair analyst K. Krum now forecasts that the medical device company will post earnings of ($0.87) per share for the year, down from their previous estimate of ($0.86). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for K2M Group’s Q1 2018 earnings at ($0.20) EPS, Q2 2018 earnings at ($0.15) EPS, Q3 2018 earnings at ($0.11) EPS, Q4 2018 earnings at ($0.06) EPS and FY2018 earnings at ($0.52) EPS.
K2M Group (NASDAQ:KTWO) last issued its earnings results on Wednesday, November 1st. The medical device company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). K2M Group had a negative return on equity of 16.02% and a negative net margin of 16.22%. The company had revenue of $62.65 million for the quarter, compared to analyst estimates of $62.69 million. During the same quarter in the previous year, the company posted ($0.19) earnings per share. The company’s quarterly revenue was up 5.6% compared to the same quarter last year.
K2M Group (NASDAQ:KTWO) opened at $20.24 on Wednesday. The company has a current ratio of 3.06, a quick ratio of 1.67 and a debt-to-equity ratio of 0.29. K2M Group has a 1 year low of $16.44 and a 1 year high of $25.99. The firm has a market cap of $876.10, a PE ratio of -21.08 and a beta of 1.34.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC lifted its holdings in shares of K2M Group by 7,765.0% in the third quarter. Cubist Systematic Strategies LLC now owns 4,719 shares of the medical device company’s stock valued at $100,000 after purchasing an additional 4,659 shares in the last quarter. Rockefeller Financial Services Inc. purchased a new stake in shares of K2M Group in the third quarter valued at about $105,000. BNP Paribas Arbitrage SA lifted its holdings in shares of K2M Group by 5,175.3% in the second quarter. BNP Paribas Arbitrage SA now owns 4,484 shares of the medical device company’s stock valued at $109,000 after purchasing an additional 4,399 shares in the last quarter. Dorsey & Whitney Trust CO LLC purchased a new stake in shares of K2M Group in the second quarter valued at about $211,000. Finally, Trexquant Investment LP purchased a new stake in shares of K2M Group in the third quarter valued at about $223,000. 97.95% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “William Blair Comments on K2M Group Holdings Inc’s FY2017 Earnings (KTWO)” was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.themarketsdaily.com/2018/01/11/william-blair-comments-on-k2m-group-holdings-incs-fy2017-earnings-ktwo.html.
About K2M Group
K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.
Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.